- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | Vicore Pharma Holding: Vicore Pharma to Participate in the Leerink Therapeutics Forum | 210 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 7, 2026 / Vicore Pharma Holding AB (NASDAQ Stockholm:VICO)(NASDAQ:VCRE), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of... ► Artikel lesen | |
| Mo | Vicore Pharma Holding AB - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| Mo | Citigroup Inc.: Citi Appointed as Depositary Bank for Vicore Pharma Holding AB's ADR Program | 274 | Business Wire | Citi Issuer Services, acting through Citibank N.A., has been appointed by Vicore Pharma Holding AB ("Vicore Pharma"), a clinical-stage biopharmaceutical company unlocking the potential of a new class... ► Artikel lesen | |
| Mo | Vicore Pharma Holding: Vicore Pharma Appoints Rob Slack as Chief Scientific Officer | 266 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 6, 2026 / Vicore Pharma Holding (STO:VICO) - Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where... ► Artikel lesen | |
| Mo | Vicore Pharma Holding AB: Vicore Pharma Appoints Rob Slack as Chief Scientific Officer | 135 | GlobeNewswire (Europe) | Dr. Slack brings over 20 years' experience in fibrosis and respiratory translational science and joins from GSK, where he served as Vice President and Head of Respiratory Biology
Stockholm, Sweden &... ► Artikel lesen | |
| 01.07. | Vicore Pharma Holding: Vicore Pharma to Commence Trading in the United States on the Nasdaq Stock Market | 1.028 | ACCESS Newswire | STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / July 1, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(Nasdaq US:VCRE), a clinical-stage biopharmaceutical company unlocking the potential... ► Artikel lesen | |
| VICORE PHARMA HOLDING AB ADR Aktie jetzt für 0€ handeln | |||||
| 02.06. | Vicore Pharma Holding: Vicore Pharma to Host Webcast to Discuss Buloxibutid and the Evolving IPF Treatment Landscape | 313 | ACCESS Newswire | STOCKHOLM, SE AND CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists... ► Artikel lesen | |
| 26.05. | Vicore Pharma Holding: Vicore Pharma to Present at the Jefferies Global Healthcare Conference | 274 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 (AT2) receptor agonists, today... ► Artikel lesen | |
| 22.05. | Vicore Pharma Holding: Vicore Pharma Pursues US Dual Listing, Files Registration Statement with the SEC | 521 | ACCESS Newswire | Proposed dual listing expected to broaden access to US investors as buloxibutid advances toward its Phase 2b readout in IPF, with no concurrent financing or share offering planned STOCKHOLM, SWEDEN... ► Artikel lesen | |
| 07.05. | Vicore Pharma Holding: Vicore Pharma Elects Peter Guenter to its Board of Directors | 402 | ACCESS Newswire | Appointment strengthens Vicore's board with nearly four decades of global pharmaceutical leadership as the company advances buloxibutid toward an important late-stage data readout STOCKHOLM, SE / ACCESS... ► Artikel lesen | |
| 06.05. | Announcement from the Annual General Meeting of Vicore Pharma Holding AB | 397 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Today on 6 May 2026, the Annual General Meeting (the "AGM") of Vicore Pharma Holding AB (publ) ("Vicore Pharma" or the "Company")(STO:VICO) was held,... ► Artikel lesen | |
| 06.05. | Vicore Pharma Holding: Interim Report January - March 2026 | 490 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 6, 2026 / Vicore Pharma Holding AB (STO:VICO) ("Vicore"), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), publishes... ► Artikel lesen | |
| 29.04. | Vicore Pharma Holding: Vicore Pharma Announces Presentations at the 2026 American Thoracic Society International Conference | 414 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 29, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), a clinical-stage biopharmaceutical company unlocking the potential of a novel class of drugs, angiotensin... ► Artikel lesen | |
| 22.04. | Vicore Pharma Holding: Vicore Pharma Completes Enrollment in the Phase 2b ASPIRE Trial of Buloxibutid in Idiopathic Pulmonary Fibrosis | 530 | ACCESS Newswire | The randomized Phase 2b ASPIRE trial successfully completed planned enrollment of over 360 patients, reflecting strong execution and robust site engagementASPIRE is designed to assess the effect of... ► Artikel lesen | |
| 01.04. | Notice Of Annual General Meeting In Vicore Pharma Holding AB | 404 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 1, 2026 / The shareholders of Vicore Pharma Holding AB (publ)(STO:VICO), reg. no. 556680-3804 (the "Company"), are summoned to the Annual General Meeting on Wednesday... ► Artikel lesen | |
| 26.03. | Vicore Pharma Holding: Vicore Publishes the Annual Report for 2025 | 401 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 26, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced... ► Artikel lesen | |
| 09.03. | Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences | 309 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Vicore Pharma Holding AB (STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs), today announced... ► Artikel lesen | |
| 05.03. | Vicore Pharma Holding: Vicore Pharma Elevates Leadership Team Ahead of Key Clinical and Corporate Milestones | 499 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 5, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)... ► Artikel lesen | |
| 27.02. | Vicore Pharma Holding: Year-End Report 2025 | 496 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 27, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists (ATRAGs)... ► Artikel lesen | |
| 26.02. | Vicore Pharma Holding: Vicore Pharma to Present at Upcoming Investor Conferences | 350 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / February 26, 2026 / Vicore Pharma Holding AB (Nasdaq Stockholm:VICO)(STO:VICO), unlocking the potential of a novel class of drugs, angiotensin II type 2 receptor agonists... ► Artikel lesen |
1 2 Weiter >>
35 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BAYER | 50,82 | -0,70 % | Paukenschlag, Kaufempfehlung und Kurschance! Renk, Bayer, Antimony Resources Aktie! | Erstellt und veröffentlicht im Auftrag von Antimony Resources Corp. Paukenschlag bei Antimony Resources. Basis für den Investmentcase war bisher die Chance, dass das Unternehmen in Kanada ein Weltklasse-Antimonprojekt... ► Artikel lesen | |
| MERCK KGAA | 141,75 | -0,74 % | Merck KGaA: DAX-Riese schluckt Bio-Techne für 11 Mrd. USD und zündet den KI-Chip-Turbo! | ||
| NOVO NORDISK | 43,430 | +0,86 % | Novo Nordisk: Charttechnisch spannend - Kurssprung voraus? | Die Aktie von Novo Nordisk arbeitet sich weiter peu à peu aus dem Tal der Tränen. Zur Stunde notiert der europäische Blue Chip wieder auf dem höchsten Stand seit dem Februar. Geht es nach den Analysten... ► Artikel lesen | |
| LB PHARMACEUTICALS | 34,290 | +2,63 % | LB Pharmaceuticals Inc: LB Pharmaceuticals Appoints Christopher Zergebel as Senior Vice President, Clinical Operations | NEW YORK, June 30, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc ("LB Pharmaceuticals" or the "Company") (Nasdaq: LBRX), a late-stage biopharmaceutical company developing novel therapies for schizophrenia... ► Artikel lesen | |
| PFIZER | 21,085 | +1,64 % | JEFFERIES stuft PFIZER INC auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Pfizer mit einem Kursziel von 34 US-Dollar auf "Buy" belassen. Mit Blick auf Vorab-Aussagen des Pharmakonzerns zu den anstehenden Quartalszahlen... ► Artikel lesen | |
| ELI LILLY | 1.082,00 | +2,99 % | Krebs-Convention Yes!Con 2026 / Lilly engagiert sich für eine bessere Versorgung von Frauen und Männern mit frühem Brustkrebs | Bad Homburg (ots) - Der Austausch zwischen Patient:innen, Angehörigen, Patientenorganisationen und Unternehmen stand im Mittelpunkt der Yes!Con 2026 in Berlin, Deutschlands größter Krebs-Convention.... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 16,215 | -4,17 % | Generate:Biomedicines: Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update | SOLAIRIA-1 AND SOLAIRIA-2 Phase 3 clinical trials for GB-0895 (anti-TSLP) continue to advance
Clinical trial sites activated for GB-4362 (MMAE neutralizer); first... ► Artikel lesen | |
| ETON PHARMACEUTICALS | 37,690 | -0,87 % | Eton Pharmaceuticals Aktie erreicht Rekordhoch von 38,6 USD | ||
| BRIGHT MINDS BIOSCIENCES | 64,54 | -3,17 % | Motorola Solutions Foundation and Calculated Genius Honor Chicagoland Future Engineers With 2026 Bright Minds, Bold Futures Scholarship | NORTHAMPTON, MA / ACCESS Newswire / June 30, 2026 / Ten extraordinary Chicagoland high school seniors recently gathered at Motorola Solutions' global headquarters in Chicago, joined by family members... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 13,030 | 0,00 % | BTIG initiates Kazia Therapeutics stock with buy on cancer drug | ||
| SCHOTT PHARMA | 18,380 | -1,71 % | Schott Pharma: Deutsche Bank sieht Trendwende: Hochstufung auf "Buy" | Deutsche Bank stuft Schott Pharma auf "Buy" hoch und hebt das Kursziel auf 22 Euro an. Analyst Friedrichs sieht den operativen Tiefpunkt als überwunden und erwartet Rückenwind in der zweiten Geschäftsjahreshälfte.... ► Artikel lesen | |
| SANOFI | 75,82 | +1,51 % | JEFFERIES stuft SANOFI auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat Sanofi vor den Quartalszahlen auf "Buy" mit einem Kursziel von 100 Euro belassen. Da sich die neue Vorstandschefin des Pharmakonzerns, Belén... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,325 | +2,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update | Reaffirms guidance to resubmit Anaphylm (dibutepinephrine) sublingual film NDA in Q3 2026Affirms existing clinical data is sufficient for submitting regulatory applications in Canada, European Union... ► Artikel lesen | |
| NOVARTIS | 137,74 | +1,25 % | GOLDMAN SACHS stuft NOVARTIS AG auf 'Sell' | NEW YORK (dpa-AFX Analyser) - Die US-Investmentbank Goldman Sachs hat das Kursziel für Novartis von 106 auf 111 Franken angehoben, aber die Einstufung auf "Sell" belassen. Die Bewertung der Schweizer... ► Artikel lesen | |
| COMPASS PATHWAYS | 11,500 | +1,77 % | Compass Pathfinder Limited: Compass Pathways Announces Six-Month Data from Second Phase 3 Trial Confirming Rapid and Durable Profile | New 6-month data supports COMP360's potential to establish a new standard of care in TRD Data from positive COMP006 Phase 3 trial demonstrates durable benefit through at least 6 months... ► Artikel lesen |
VICORE PHARMA HOLDING AB ADR gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 15,025 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu VICORE PHARMA HOLDING AB ADR finden Sie auf Wallstreet Online.